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ABSTRACT
Introduction: This study aimed to assess the
costs and benefits of three alternative second-
line treatment strategies for Swedish patients
with type 2 diabetes mellitus (T2DM) who fail
to reach glycated hemoglobin (HbA1c) B 7%
with metformin treatment alone: glucagon-like
peptide-1 (GLP-1) receptor agonists, dipeptidyl
peptidase-4 (DPP-4) inhibitors, and neutral
protamine Hagedorn (NPH) insulin.
Methods: A previously developed cohort model
for T2DM was applied over a 35-year time
horizon. Data on T2DM patients on
metformin monotherapy with HbA1c[7%
were collected from the Swedish National
Diabetes Register. Treatment effects were taken
from published studies. Costs and effects were
discounted at 3% per annum, and the analysis
was conducted from a societal perspective. The
robustness of the results was evaluated using
one-way and probabilistic sensitivity analyses.
Results: Treatment with GLP-1 agonists was
associated with a discounted incremental
benefit of 0.10 and 0.25 quality-adjusted life
years (QALYs) and higher discounted costs of
Swedish Krona (SEK) 34,865 and SEK 40,802
compared with DPP-4 inhibitors and NPH
insulin, respectively. Assuming willingness-to-
pay (WTP) of SEK 500,000 per QALY, treatment
strategy with GLP-1 agonists was a cost-effective
option with incremental cost-effectiveness
ratios of SEK 353,172 and SEK 160,618 per
QALY gained versus DPP-4 inhibitors and NPH
insulin, respectively. The results were most
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sensitive to incidence rate of moderate/major
hypoglycemia and disutilities associated with
insulin treatment, body mass index (BMI), and
hypoglycemia.
Conclusion: Assuming a WTP of SEK 500,000
per QALY, treatment strategy with GLP-1
agonists is a cost-effective strategy in
comparison to DPP-4 inhibitors and NPH
insulin among T2DM patients inadequately
controlled with metformin alone in a Swedish
setting.
Keywords: Cost–utility analysis; DPP-4
inhibitors; GLP-1 agonists; Insulin; Sweden;
Type 2 diabetes
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a serious
progressive disorder characterized by insulin
resistance and relative insulin deficiency
resulting in increased blood glucose level. The
prevalence of T2DM is growing worldwide,
mainly due to growth in urbanization and the
resulting substantial changes in lifestyle [1]. The
total number of adults aged 20–79 with diabetes
is projected to increase from 382 million in
2013 to 592 million in 2035 [1]. It has been
estimated that 6.4% of adults aged 20–79 had
diabetes in Sweden in 2013 [1]. T2DM is the
most common form of diabetes worldwide, and
is an established risk factor for several fatal and
non-fatal micro- and macrovascular
complications. This translates into a
significant economic burden for individuals
and societies. In 2010, an estimated 8% of the
total Swedish health expenditure went to
diabetes-related healthcare [2].
Previous studies have shown that good
glycemic control is crucial to decrease the risk
of diabetes-related complications [3–6]. The
American Diabetes Association recommends
glycated hemoglobin (HbA1c)\7% as
treatment goal for most patients with T2DM
[7], and the year 2010 guidelines from the
National Board of Health and Welfare in
Sweden advocates similar treatment goals for
newly diagnosed, people who were diagnosed at
younger age, and people with low risk of
cardiovascular diseases [8]. A typical treatment
pattern for T2DM, advocated by international
and Swedish guidelines, begins with lifestyle
modifications, then adds metformin
monotherapy when blood glucose control is
unsatisfactory, followed by the addition of
other medication such as sulfonylurea or basal
insulin including intermediate-acting neutral
protamine Hagedorn (NPH) insulin. The
progressivity of the disease implies that many
patients eventually will need multiple dose
insulin treatment if second-line treatment
does not result in achievement of sufficient
control of blood glucose levels [8–10].
Despite these guidelines and the availability
of a range of drugs, a large proportion of T2DM
patients fail to achieve and maintain the
treatment goals, mainly due to the progressive
nature of the disease and the inadequacy of
conventional treatments [11]. A survey
conducted in 2008 by the Swedish National
Diabetes Register showed that while there was
an improvement in the proportion of T2DM
patients reaching HbA1c B 7% compared with
1999, a substantial proportion of patients (48%)
still did not achieve this treatment goal [12].
Similar values have been reported for years
2009–2012 [13]. In addition, conventional
medications such as sulfonylurea or insulin are
associated with side effects including weight
gain and hypoglycemia [14, 15]. Hence, there is
a need for new therapies with better efficacy and
fewer side effects.
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In response to this, incretin-based therapies
have attracted growing interests during recent
years, as clinical trials indicated that they might
provide improved glycemic control with low
risk of hypoglycemia and seem weight neutral,
or even weight reducing [14, 16–18]. These
therapies are mainly recommended as second-
line therapy among patients who fail to achieve
or maintain the blood glucose treatment goals
on metformin alone [10]. Two classes of
incretin-based therapies are available:
glucagon-like peptide-1 (GLP-1) receptor
agonists and dipeptidyl peptidase-4 (DPP-4)
inhibitors. Currently, two GLP-1 agonists
(liraglutide and exenatide) and three DPP-4
inhibitors (sitagliptin, saxagliptin, and
vildagliptin) have been approved for use in
Sweden.
While the short-term treatment efficacy and
safety of incretin-based therapies have been
investigated, there is limited evidence on the
long-term efficacy and cost-effectiveness of
these therapies. Increased use of these newer,
more expensive drugs in routine practice has
substantial budgetary implications for health
systems. Moreover, while there is consensus on
using metformin as the first-line oral
anti-hyperglycemic alongside lifestyle
modifications in T2DM patients when lifestyle
interventions are insufficient for glycemic
control, there is disagreement over the
preferred agent for second-line therapy [19].
Hence, it is of value to evaluate and compare
the cost-effectiveness of these second-line
therapies to aid well-informed decisions
regarding second-line therapy for patients with
T2DM inadequately controlled by metformin
monotherapy. The aim of this study was to
estimate the lifetime costs and benefits of three
second-line treatment alternatives: adding GLP-
1 agonists, DPP-4 inhibitors, or NPH insulin to
metformin among T2DM patients failing to
reach HbA1c B 7% with metformin alone in
Sweden. In addition, considering the treatment
strategies included in this study, we implicitly
evaluated the cost-effectiveness of starting NPH
insulin as the second-line therapy or later as




The authors conducted this cost–utility analysis
using the Swedish Institute for Health
Economics Cohort Model for T2DM (IHECM-
T2DM). This model was previously described
and used to compare cost-effectiveness of
liraglutide versus sulphonylurea or sitagliptin
in Sweden [20]. The IHECM-T2DM is a cohort
model consisting of two parallel Markov chains
covering 120 microvascular health states and
100 macrovascular health states. The
microvascular health states include three
subgroups: retinopathy, neuropathy, and
nephropathy based on the work of Eastman
et al. [21], Brown et al. [22], and Bagust et al.
[23]. The macrovascular health states include
four subgroups: ischemic heart disease,
myocardial infarction, stroke and, heart failure
based on United Kingdom Prospective Diabetes
Study (UKPDS) Outcomes Models [24, 25] and
the Swedish National Diabetes Register
(NDR) equations [26]. For macrovascular
complications, in the current study, the
authors used equations from the NDR [26] in
the base case and from the UKPDS Outcome
Model-1 [24] in a sensitivity analysis. With this
structure, patients can develop multiple
complications within each model cycle and
over the simulation period. The IHECM-T2DM
has a yearly cycle and a time horizons of up to
40 years can be used. In addition, the user can
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choose between two sets of mortality risk
equations [24, 25]. The authors used the
UKPDS Outcome Model-1 [24] for mortality in
this study.
The model also includes evolution of
biomarkers over time, treatment algorithms,
and treatment-related side effects such as
hypoglycemia. Eight biomarkers are included
in the model and evolution of these biomarkers
over time is determined by the initial treatment
effects and an annual drift. Treatment
algorithms include up to eight changes in
anti-hyperglycemic treatment composition to
account for possible combinations of glucose-
lowering agents and treatment intensifications;
this algorithm depends on a user-defined
switching threshold of HbA1c. The model
starts with assigning baseline clinical and
demographic characteristics of the cohort,
history of complications before diagnosis, and
prevalence of diabetes-related complications.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Simulation Cohort, Treatment Effects
and Scenarios
The baseline characteristics of the simulated
cohort were based on a survey conducted by the
Swedish National Diabetes Register [27]. As in
this study, the authors evaluated the three
second-line therapies as add-on to metformin,
they used the data on a sample of patients on
metformin monotherapy with HbA1c[7%
consisting 30% of patients on metformin
monotherapy in Ekstrom et al.’s study [27]
(Table 1, data were provided by the Swedish
National Diabetes Register).
Three treatment strategies evaluated in the
study are presented in Fig. 1. In strategies 1 and
2, patients received the GLP-1 receptor agonists
and the DPP-4 inhibitors as add-on to
metformin, respectively. In both these
strategies, patients progressed to NPH insulin
40 insulin units (IU)/day ? metformin when
HbA1c exceeded 7.5% and to intensified NPH
insulin 60 IU/day ? metformin when HbA1c C
8% (the base case analysis). In sensitivity
analyses, these HbA1c threshold values
changed to 8% (switch to NPH insulin 40 IU/
day) and 8.5/9% (switch to NPH insulin 60 IU/
day). In strategy 3, patients received NPH
insulin 40 IU/day ? metformin as initial
second-line treatment, then progressed to NPH
insulin 60 IU/day ? metformin on reaching the
HbA1c threshold value of 8% (the base case
analysis) and 8.5/9% (the sensitivity analyses).
Table 1 Baseline characteristics of patients on metformin
monotherapy with HbA1c[7% in the Swedish National
Diabetes Register (NDR)
Variable N Value (–SD)
Age (years) 12,172 64.7 ± 11.6
Diabetes duration (years) 10,988 5.6 ± 4.6
Male (%) 7,000 57.5
Smoker (%) 1,710 17.5
HbA1c (%) 12,172 7.7 ± 0.8
Systolic BP (mmHg) 11,649 137 ± 16
Diastolic BP (mmHg) 11,649 79 ± 9
Total cholesterol (mmol/l) 9,381 4.9 ± 1.1
HDL (mmol/l) 8,322 1.2 ± 0.3
LDL (mmol/l) 7,355 2.8 ± 0.9
Triglycerides (mmol/l) 8,200 2.1 ± 1.3
BMI 10,385 30.9 ± 5.3
BMI body mass index, BP blood pressure, HbA1c glycated
hemoglobin, HDL high-density lipoprotein, LDL low-
density lipoprotein, SD standard deviation
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Comparing strategy 3 with strategies 1 and 2
would provide more insight about timing of
insulin initiation in T2DM patients. In the
current study, the GLP-1 receptor agonists
included liraglutide 1.2 mg daily and
exenatide 2 mg once weekly, and the DPP-4
inhibitors are sitagliptin 100 mg daily,
saxagliptin 5 mg daily, and vildagliptin
100 mg daily.
Treatment effects were considered as
absolute change from baseline in HbA1c and
weight and the rates of mild, moderate, and
major hypoglycemia (Table 2) [28–34]. The
treatment effects for each drug class were
extracted from the literature; where data at
drug class level were not available, the authors
used data from head-to-head randomized
controlled trials for a single agent in each drug
class. The model considers non-severe daytime
hypoglycemia as mild and non-severe nocturnal
hypoglycemia as moderate hypoglycemia.
The authors used data from the literature to
estimate the treatment effects due to
intensification of insulin from 40 IU/day to
60 IU/day [35, 36]. A recent meta-analysis
found no direct association between dosage of
insulin and risk of hypoglycemia [37], and so
the authors applied the same rate of
hypoglycemia events for both insulin
treatments in this study. To account for
association between hypoglycemic events and
changes in HbA1c, the reported event rate from
a study is transferred to expected event rate
using coefficient (1.43) from a previous study
[38].
As in previous studies, no treatment effect on
other biomarkers was assumed in the base case
analysis [39–42]. This assumption was relaxed
in the sensitivity analysis. When data on
treatment effects of NPH insulin were not
available, the authors used the results from
glargine insulin, since previous studies reported
no significant difference in treatment effects
between NPH and glargine insulin [43–45].
Treatment effects were applied for the first
year after treatment, and then a constant
annual drift was assumed for different
treatment strategies. An annual drift of 0.15%
unit for HbA1c was assumed for all treatments
[46]. The annual drifts in weight were 0.42 kg
for insulin and 0.23 kg for other treatments in
the base case analysis [47]. In the sensitivity
analyses, the authors considered 0.23 kg and
0.1 kg change in weight for all treatments [48].
They assumed 0.3 mmHg and 0.03 mg/dl
annual drifts in blood pressure and lipid levels,
Fig. 1 Schematic of treatment strategies applied in the base case analysis. DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-
like peptide-1, HbA1c glycated hemoglobin, IU insulin units
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respectively [49]. Prevalence of T2DM-related
complications at baseline was extracted from
national and international published sources
[26, 50, 51].
Costs and Utilities
In the base case, costs were accounted from a
societal perspective (2013 Swedish krona, SEK, 1
SEK = 0.115 Euros) and included healthcare
costs, productivity losses, and net
consumption losses. Costs for drugs, self-
monitoring blood glucose (SMBG) test strips,
and SMBG lancets were collected through the
Dental and Pharmaceutical Benefits Agency in
Sweden (TLV) [52]. In the base case analysis, the
authors calculated a weighted average cost for
GLP-1 agonists and DPP-4 inhibitors according
to consumption of single agents in each class in
Sweden in 2013, while in a sensitivity analysis,
they applied the price of the lowest cost agent
for each drug class (liraglutide for GLP-1
agonists class and vildagliptin for DPP-4
inhibitors class). In the base case analysis,
based on recommendations by Owens et al.
[53], the authors assumed that no SMBG is
required for patients on DPP-4 inhibitors and
GLP-1 agonists regimens, and daily monitoring
is required for patients on NPH insulin
regimens. It was assumed that patients use a
new strip and lancet for each SMBG. Costs
associated with T2DM-related complications
and treatment side effects were derived from
Sweden-specific published sources adjusted for
2013 using the Swedish Consumer Price Index
(Table 1 in supplement).
Productivity losses were measured using
human capital approach. Due to lack of data
on productivity losses due to T2DM-related
complications, we assumed that only severe
stages of micro- and macrovascular
complications caused loss of production.
Annual cost of consumption includes costs in
added life years and is calculated as the









Change in HbA1c (%) -0.96 [28] -0.69 [28] -1.12 [28] -0.69
Change in body weight (kg) -1.80 [28] 0.00 [28] 3.30 [28] 1.80
Mild hypoglycemia (per patient per year) 0.14 [29] 0.14 [29] 3.16 [30] 3.16 [30]
Moderate hypoglycemia (per patient per year) 0.05 [31] 0.07 [30] 1.014 [32] 1.014 [32]
Major hypoglycemia (per patient per year) 0.006 [29] 0.01 [30] 0.06 [33] 0.06 [33]
Systolic blood pressure (mmHg) -3.20 [34] -4.00 [30] -2.00 [30] 0.00
Diastolic blood pressure (mmHg) -1.60 [34] -1.47 [29] -1.00 [30] 0.00
Total cholesterol (mmol/l) -0.01 [29] 0.00 [30] -0.20 [30] 0.00
HDL cholesterol (mmol/l) 0.01 [29] 0.01 [29] 0.00 [30] 0.00
LDL cholesterol (mmol/l) 0.09 [29] 0.09 [29] -0.10 [30] 0.00
Triglyceride (mmol/l) -0.10 [29] -0.23 [29] -0.40 [30] 0.00
DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, HbA1c glycated hemoglobin, HDL high-density lipoprotein,
IU insulin units, LDL low-density lipoprotein, Met metformin, NPH neutral protamine Hagedorn
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difference in market consumption and
production during gained life years. Including
these costs is required by the TLV in Sweden.
For the current study, these costs were extracted
from a previous study in Sweden [54] inflated to
year 2012 using consumer price index (see
supplement for more details).
Baseline utility was modeled using data from a
recent study on EQ-5D scores in Swedish T2DM
patients with no complications [55]. Health state
utilities for T2DM-related complications and
utility decrements associated with age, gender,
duration of diabetes, and BMI were derived,
whenever possible, from Sweden-specific
published sources, supplemented with data
from other sources if necessary (Table 2 in
supplement). The same utility decrement was
applied for subsequent events as for the initial
one. No utility decrement associated with
modality of treatment was applied in the base
case analysis. Decrement associated with
hypoglycemia was extracted from a previous
study [56] which used data from the Swedish
respondents in a multinational study [57]. A 3%
annual discount rate for costs and quality-
adjusted life years (QALYs) was applied in the
base case analysis over a 35-year time horizon.
While there is no formal willingness-to-pay
(WTP) threshold for cost-effectiveness ratios in
Sweden, interventions with less than 500,000
SEK per QALY gained are generally considered as
cost-effective [58, 59].
Sensitivity Analyses
The authors conducted a series of one-way
sensitivity analyses to assess the impact of
variation in the model inputs and assumptions
on the results of the base case analysis. In a
sensitivity analysis, they excluded the net
consumption and productivity losses (applying
healthcare payer perspective). The number of
weekly SMBG performed by patients in the GLP-
1 agonists ? metformin and DPP-4 inhibitors ?
metformin groups was varied (3, 5, and 7), as
were the time horizons (10 and 20 years) and
the discount rate for costs and QALYs (0 and
5%). A utility decrement of 0.049 for insulin
therapy was applied [60]. The annual drift in
HbA1c was set to 0.10% and 0.20% unit, the
cost of one SMBG was varied by 10% and 25%,
and the cost of T2DM-related complications
varied by ±20%. No major hypoglycemia and
no moderate/major hypoglycemia were
assumed for all treatment groups. The
treatment effects on HbA1c were changed to
the lower and upper limits of 95% CI of the
main estimate [28]. In addition, the treatment
effect on HbA1c for NPH insulin 60 IU/day was
set to -0.56%, -0.35% [35], and -0.18% [37].
A probabilistic sensitivity analysis (PSA) was
conducted to assess the joint uncertainty of the
input parameters using a Monte Carlo
simulation with 1,000 iterations. Non-
parametric bootstrapping with 1,000 bootstrap
samples was then used to calculate the mean and
bootstrap bias-corrected (BBC) 95% confidence
interval (CI) of costs and QALYs as well as
incremental cost-effectiveness ratios (ICERs). In
the PSA, standard errors for utility decrement and
treatment effects were collected from related
sources. Costs of treatments and T2DM-related
complications varied within a range of 20% from
the base case values. Microsoft Excel and STATA
13 (StataCorp LP, College Station, TX, USA) were
used for the analyses.
RESULTS
The simulated profiles of HbA1c change over
time for three treatments as add-on to
metformin are shown in Fig. 2. It can be seen
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that using the base case threshold values, before
switching to insulin therapy, patients on
strategies 1 and 2 were expected to receive
GLP-1 agonists and DPP-4 inhibitors,
respectively, for 6 and 4 years. Figure 1 in the
supplement displays the 35-year cumulative
incidence of some major micro- and
macrovascular events projected by the IHECM-
T2DM. The model predicted a higher incidence
of macrovascular events compared with








1 versus strategy 2
Difference strategy
1 versus strategy 3
Difference strategy
2 versus strategy 3
Discounted
QALYs
4.75 4.65 4.50 0.10 0.25 0.15
Discounted costs
Healthcare costs 501,594 470,084 471,996 31,510 29,598 -1,912
Productivity
losses




1,652,341 1,648,485 1,639,510 3,857 12,831 8,974
Total costs 2,162,907 2,128,042 2,122,105 34,865 40,802 5,936
ICER (SEK) 353,172 160,618 36,050
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life years, SEK Swedish Krona
Fig. 2 Simulated proﬁles of HbA1c in the treatment strategies over the modeled time horizon. HbA1c glycated hemoglobin
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microvascular events. For all events, the lowest
and highest incidences were observed in the
strategies 1 and 3, respectively.
The results of cost–utility analysis for the
base case are given in Table 3. Treatment
strategy 1 was associated with an 0.10 and
0.25 units improvement in discounted QALYs
compared with strategies 2 and 3, respectively.
In addition, treatment strategy 2 was associated
with an improvement of 0.15 discounted
QALYs compared with strategy 3. On the other
hand, from a societal perspective, the treatment
strategy 1 was associated with SEK 34,865 and
SEK 40,802 higher discounted costs compared
with strategies 2 and 3, respectively. The ICERs
for strategy 1 versus strategies 2 and 3 were SEK
353,172 and SEK 160,618, respectively, and the
ICER for strategy 2 versus strategy 3 was SEK
36,050. Assuming a WTP of SEK 500,000 per
QALY gained in Sweden, strategy 1 could be
considered cost-effective compared to either
strategies 2 and 3.
Sensitivity Analysis
Overall, the univariate analyses showed that our
base case analysis was robust to variation in the
inputs and assumptions applied in the model.
Figure 3 presents the results of the univariate
sensitivity analyses as percentage changes in the
ICER from the base case for comparison of
strategy 1 versus strategy 2. The disutility
associated with every unit of BMI over 25
(0.006 in the base case) was a key driver of the
results, and excluding it from the analysis
caused the ICER to rise to SEK 661,917, an
Fig. 3 Results of one-way sensitivity analyses: strategy 1
versus strategy 2. BMI body mass index, CI conﬁdence
interval, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-
like peptide-1, HbA1c glycated hemoglobin, IU insulin
units, SMBG self-monitoring blood glucose
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87.3% increase from the base case. While the
result of the base case was sensitive to HbA1c
threshold values, disutility due to mild/
moderate hypoglycemia and insulin treatment,
and incidence of moderate/major
hypoglycemia, in all these cases the ICER
remained below SEK 500,000 (range: SEK
204,517–495,368). In the PSA, the estimated
ICER was SEK 319,217 (BBC 95% CI: SEK
309,849–330,212). Assuming a WTP of SEK
500,000 per QALY gained, strategy 1 had a
74.7% likelihood of being considered cost-
effective in comparison to strategy 2.
The results of the univariate sensitivity
analyses for strategy 1 versus strategy 3 are
shown in Fig. 4 as percentage changes in the
ICER from the base case. The key model drivers
were disutility of mild/moderate hypoglycemia,
the disutility of insulin and BMI over 25, and
incidence of moderate/major hypoglycemia.
However, in all these cases, the ICER remained
below SEK 500,000 (range: SEK
85,629–256,830). The PSA showed that the
ICER was SEK 153,277 (BBC 95% CI: SEK
150,788–155,766). Assuming a WTP of SEK
500,000 per QALY gained, strategy 1 was
expected to have a 100% probability of being
cost-effective in comparison to strategy 3.
Figure 5 displays the results of the univariate
sensitivity analyses for strategy 2 versus strategy
3 as percentage changes in the ICER from the
base case. The key model drivers were incidence
of moderate/major hypoglycemia, the disutility
of mild/moderate hypoglycemia, including
costs of 7 SMBG per week for the DPP-4
inhibitors, and the disutility of insulin. None
Fig. 4 Results of one-way sensitivity analyses: strategy 1
versus strategy 3. BMI body mass index, CI conﬁdence
interval, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-
like peptide-1, HbA1c glycated hemoglobin, IU insulin
units, SMBG self-monitoring blood glucose
600 Diabetes Ther (2014) 5:591–607
of these changes had a significant impact on the
cost–utility conclusions. Moreover, excluding
net consumption and productivity loss, and
applying the price of the cheapest DPP-4 agent,
translated into dominance of strategy 2 versus
strategy 3. The estimated ICER ranged from SEK
18,630 to SEK 69,976. The ICER from the PSA
was SEK 40,277 (BBC 95% CI: SEK
37,436–43,119). Assuming a WTP of SEK
500,000 per QALY gained, strategy 2 was
expected to have a 98.1% probability of being
cost-effective in comparison to strategy 3.
DISCUSSION
The authors applied a cohort model (IHECM-
T2DM) to examine the long-term costs and
health benefits of three different treatment
strategies as add-on to metformin
monotherapy in a representative sample of
T2DM patients not achieving HbA1c\7% on
metformin monotherapy in Sweden. The results
show that, assuming a WTP value of 500,000
SEK, the treatment strategy with GLP-1 agents is
cost-effective in comparison to treatment
strategies with either DPP-4 inhibitors or NPH
insulin from both a societal and a healthcare
payer perspective. Compared with treatment
strategies of DPP-4 inhibitors and NPH insulin,
the cost per QALY gained with GLP-1 agonists
was approximately SEK 353,000 and SEK
161,000, respectively. The results from this
study indicate that later transition to NPH
insulin (i.e., as third-line therapy after
providing incretin-based therapies) is cost-
effective with the ICERs less than 200,000 SEK.
Fig. 5 Results of one-way sensitivity analyses: strategy 2
versus strategy 3. BMI body mass index, CI conﬁdence
interval, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-
like peptide-1, HbA1c glycated hemoglobin, IU insulin
units, SMBG self-monitoring blood glucose
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While there was no significant difference in
hypoglycemic episodes between GLP-1 agonists
and DPP-4 inhibitors, GLP-1 agonists were
associated with a higher reduction in HbA1c
and greater weight loss. These effects influence
health outcomes in two ways: first, there is a
direct effect in terms of lower cumulative
incidence of T2DM-related complications, and
second, there is an indirect effect through delay
in switching to NPH insulin. The higher
reduction in HbA1c meant that patients on
GLP-1 agonists initiated NPH insulin therapy
later than patients on DPP-4 inhibitors,
resulting in fewer expected episodes of
hypoglycemia in the lifetime perspective.
These health benefits partly offset the higher
price of GLP-1 agonists compared with DPP-4
inhibitors, and this is in line with previous
modeling studies comparing liraglutide with
sitagliptin [20, 61–63]. The one-way sensitivity
analyses in this study showed that this finding
was most sensitive to the disutility due to BMI:
assuming no disutility due to BMI [25 resulted
in an ICER higher than SEK 500,000 per QALY
gained. This is mainly due to significant
difference between these two drug classes in
weight changes (1.8 kg reduction versus no
change) and implies that besides the effects on
improved glycemic control, the effects on
weight also play important role in cost-
effectiveness of treatments in the T2DM
context. In line with a previous study [62],
this finding suggests that there should be a sub-
group of patients with BMI [25 where
treatment strategy with GLP-1 agonists is even
more cost-effective in comparison to DPP-4
inhibitors. In particular, a previous study in
Sweden showed that BMI is a significant
predictor of other biomarkers in T2DM
patients [64]. This implies that taking this
association into account might decrease the
ICER in favor of GLP-1 agonists, due to its effect
on weight loss. The results were robust to other
assumptions, and the ICER remained below SEK
500,000.
The ICER reported in the current study is
higher than in a previous study in Sweden [20]
that used the same model to compare liraglutide
versus sitagliptin. Differences in utility
decrement, the baseline characteristics, and
treatment effects might be potential
explanations for different ICER values. The ICER
is also higher than in previous studies in other
countries [61–63]. Beside differences mentioned
earlier, there are differences in perspective
(societal versus healthcare payer), and applied
model that limits comparability of this study with
previous ones. All these studies applied the CORE
diabetes model [65], which mainly uses risk
equations from the UKPDS Outcome Model-1
[24] for macro- and microvascular complications.
The authors used a different model (i.e., the
IHECM-T2DM), which applies different risk
equations including Swedish-specific
macrovascular risk equations [21–23, 26].
In the comparison of incretin-based
therapies against NPH insulin, while NPH
insulin was associated with higher HbA1c
reduction, it resulted in weight gain and a
higher number of hypoglycemic episodes. The
estimated ICER of both incretin-based second-
line treatment strategies (1 and 2) remained
below SEK 500,000. This finding is in line with a
previous cost–utility analysis comparing the
DPP-4 inhibitor saxagliptin against NPH
insulin as add-on to metformin in Poland [39].
In these treatment strategies, patients on
incretin-based therapies benefit from an extra
treatment compared with patients who initiate
NPH insulin as second-line treatment, and this
finding implies that the health benefits of
providing second-line treatment prior to
insulin introduction offset the higher prices of
these medications.
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However, it should be noted that the cost-
effectiveness of incretin-based therapies
decreased as the HbA1c switching threshold
value to NPH insulin increased. This implies
that as the number of years on these treatments
increases, the marginal costs of the treatments
outweigh the marginal benefits, and the ICER
rises. The similar finding was observed in a
previous study in Sweden using the same model
[20]. The one-way sensitivity analyses showed
that the results were most sensitive to the
assumptions related to incidence of
hypoglycemia and disutility of hypoglycemia
and insulin. However, this base case conclusion
was robust against all these variations.
The main strengths of the current study
include: applying the baseline characteristics
from a large sample of T2DM patients from
routine practice in Sweden, using utility
decrements for a number of complications
from a Swedish sample with T2DM, applying
Swedish-specific risk equations for
macrovascular complications, and extracting
treatment effects on the main biomarkers (i.e.,
HbA1c and weight) from a meta-analysis
instead of a single clinical trial. In addition,
the authors used HbA1c threshold to determine
the treatment pathway, reflecting clinical
practice and national guidelines. These
strengths improve the external validity and
relevance of these results for policy making in
the Swedish setting.
The results of the current study should be
interpreted in light of a number of cautions.
The authors included only hypoglycemia as a
treatment-related adverse event in the model.
The results of the 1860-LIRA-DPP-4 (liraglutide
dipeptidyl peptidase-4 inhibitor) trial showed
no significant difference in other adverse events
between liraglutide and sitagliptin [29]. On the
other hand, previous studies [30, 66] reported
higher episodes of non-hypoglycemia-related
adverse events such as nausea for GLP-1 and
DPP-4 agents compared with insulin glargine. If
insulin glargine and NPH insulin are
comparable with respect to adverse events,
then the authors’ reported ICERs in comparing
GLP-1/DPP-4 against NPH insulin are
underestimated to some extent. However, the
authors do not expect this to have influenced
the final conclusion, as these ICERs are long
way from our assumed SEK 500,000 WTP value.
As they had no clinical trial data regarding the
effects of treatment on diabetes-related
complications, the authors applied the
commonly used method of using biomarkers
(e.g., HbA1c and weight) as surrogate markers
for these complications. Due to lack of data, the
authors did not take into account the
possibilities of treatment discontinuation by
patients and different annual drifts for
different treatments. This limits the
generalizability of these findings. However,
these are common modeling practices, and the
authors tried to consider the possibility of
different annual drifts in the PSA, assuming a
normal distribution for annual drift in
biomarkers. It should be mentioned that their
conclusions are based on a baseline HbA1c of
7.7% ± 0.8, and generalizability to patients with
lower and higher HbA1c values at baseline is
limited. Especially, as it was recommended by
the American Diabetes Association and the
European Association for the study of
Diabetes, starting treatment with insulin
should be strongly considered for patients
with dramatically high HbA1c or significant
hyperglycemic symptoms [10]. Pooling agents
into classes (i.e., GLP-1 and DPP-4) implies that
agents within a drug class have similar efficacy.
The results of meta-analysis on individual
agents in the authors’ main source (i.e., Ref.
[28]) supported this assumption and
conducting the class-level analysis.
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CONCLUSION
From both a societal and a healthcare payer
perspective, treatment with GLP-1 agonists is a
cost-effective treatment strategy in comparison
to DPP-4 inhibitors and NPH insulin as second-
line therapy among T2DM patients
inadequately controlled with metformin alone
in a Swedish setting.
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